SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN
Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It
is recommended both for treatment naive and experienced patients. We evaluated the safety and
efficacy of this combination in naïve chronic HEP-C G3 patients.
Methods: We prospectively enrolled 50 chronic HEP-C G3 treatment naïve patients.
Patients with de-compensated cirrhosis, platelets count<100, portal vein size >13 mm on ultrasound in
size were excluded.
Eligible patients were enrolled to receive Sovaldi 400mg daily, Ribavirin 10 mg/Kg body weight and
Pegylated interferon 1.5 UCG/KG body weight for 12 weeks.
Patients were seen in outpatient 4-weekly basis. They had baseline CBC, TSH, Blood Sugar, HCV
Genotype, and HCVPCR quantitative. Each patient had CBC at every 4 weeks. RVR at treatment week 4,
and ETR (End of Treatment) at weeks 12 were defined by HCV RNA <25 IU/mL.
Results: This is our ongoing study we are presenting interim analysis of 50 patients who have
completed 12 weeks of treatment.
Out of 50 patients 75% were male, 25 % were female with median age 48 years. 48 patients out of 100
(96%) were PCR negative at week 4 and 96% were PCR negative at week 12 respectively. Two patients
did not achieve RVR, and they did not achieve ETR either.
The most common AEs were nausea, fatigue, dizziness.
Conclusions: Sofosbuvir + Ribavirin+PEG INF in HCV-G3 infected patients are very effective treatment.
Most patients achieved rapid Virologic response without any major side effects. These patients are
under regular review to monitor SVR.
Professor Gill and his team is seeing patients in person Observing and Practicing COVID-19 prevention guidelines Physicians rooms and waiting areas Are fully sanitized Patients and attendants are provided masks , gloves and sanitizer at the entry of the premises